April 13, 2023 12:01 AM EDTUpdated 06:47 AM

Biopharma venture funding falls to the lowest total since 2019 as startups ponder alternative paths

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Venture capital investments in biotech and pharma hit a more than three-year low last quarter as a prolonged market downturn forced difficult next-step decisions for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biopharma venture funding falls to the lowest total since 2019 as startups ponder alternative paths

Kyle LaHucik

Senior Reporter

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Takeda to pay $200M for rights to anemia drug from Keros

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Revolution sells $600M in shares on back of RAS inhibitor portfolio updates

Gilead makes another ADC move, inking up to $415M pact with Tubulis

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Bio­phar­ma ven­ture fund­ing falls to the low­est to­tal since 2019 as star­tups pon­der al­ter­na­tive paths

Senior Reporter

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

Biopharma venture funding falls to the lowest total since 2019 as startups ponder alternative paths